About The Study: Preexposure prophylaxis (PrEP) use increased between 2013 and 2023, with generic tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) being the most frequently prescribed medication since 2021. Injectable PrEP use was low likely because of barriers such as the high cost of stocking this expensive medication in clinics.
Corresponding Author: To contact the corresponding author, Laura M. Mann, PhD, MPH, email lmann@cdc.gov .
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jama.2024.21493)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.21493?guestAccessKey=5a0d1022-a506-42cf-a93b-2546d78fea11&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=101424
JAMA